Upload
others
View
0
Download
0
Embed Size (px)
Citation preview
Pfizer Position on Antimicrobial Resistance Management
Kirill Tverskoy, Medical Director Pfizer Russia February 21, 2017
Objectives and Trends of Nowadays Healthcare Environment
2
Effective and innovative
technologies in healthcare
Invasive methods of diagnostics and
treatment
Increasing amount of elderly patients and
patients with chronic diseases
Growth of hospital associated/acquired infections rate
Increasing use of antimicrobial agents
Spread of antibiotic and antifungal resistant strains
More aggressive antimicrobial treatment (AMT)
OUTCOMES: • Decreased efficacy of antimicrobial agents • Significant economic burden due to high AI treatment cost, treatment
of complications
“Alliance of clinical microbiologists and chemotherapists”’ data presented at Annual Congress of Federation of Reanimatologists and anestesiologists in Sept, 2016)
3 3
Improve awareness and understanding of antimicrobial resistance through effective communication, education and training
Strengthen the knowledge and evidence base through surveillance and research
Reduce the incidence of infection through effective sanitation, hygiene and infection prevention measures
Optimize the use of antimicrobial medicines in human and animal health
Develop the economic case for sustainable investment that takes account of the needs of all countries, and increase investment in new medicines, diagnostic tools, vaccines and other interventions
WHO Global Action Plan on Antimicrobial Resistance (2015)
http://apps.who.int/iris/bitstream/10665/193736/1/9789241509763_eng.pdf
4
International Initiatives in Management of Infectious Diseases
INNOVATIVE MEDICINES INITIATIVE (IMI) - Uniting European researchers in the fight against antibiotic resistance1:
• the world’s largest public-private partnership in health care. IMI is improving the environment for pharmaceutical innovation in Europe by engaging and supporting networks of industrial and academic experts in collaborative research projects.
“GENERATING ANTIBIOTIC INCENTIVES NOW (GAIN)” ACT2
• Special legislation conditions for Qualified Infectious Disease Product (including ABx) stimulating development of AIA (fast-track review, additional exclusivity and others) :
THE 10X’20 INITIATIVE: PURSUING A GLOBAL COMMITMENT TO DEVELOP 10 NEW ANTIBACTERIAL DRUGS BY 20203
• Initiated by IDSA (Infectious Disease Society of America) and combining of efforts of USA and EU in ABx development
1. http://www.imi.europa.eu/sites/default/files/uploads/documents/Press%20Releases/IMIpressRelease6thCallFINAL.pdf. 2. http://thehill.com/images/stories/blogs/healthwatch/gainact.pdf 3. https://www.ohe.org/publications/new-drugs-tackle-antimicrobial-resistance-analysis-eu-policy-options
5
21st CENTURY CURES ACT (USA) • expedite the process by which new high priority drugs (including AIA) are
approved by easing the requirements, allows companies to provide "data summaries" and "real world evidence" such as observational studies, insurance claims data, patient input rather than full clinical trial results
International initiatives expediting the approval of new AIA
ADAPTIVE PATHWAYS PILOT (EU) • seeks to balance timely access for patients who are likely to benefit most from
the medicine with the need to provide adequate evolving information on the benefits and risks of the medicine itself.
https://www.congress.gov/bill/114th-congress/house-bill/34/text https://www.gov.uk/government/publications/health-matters-antimicrobial-resistance/health-matters-antimicrobial-resistance Canas BS et al. Med Intens, Dec 2014
6
Stagnation in development and registration on new anti-infective agents (AIA)
FDA approvals of new ABx
in1983–2012
Boucher HW, Talbot GH, Benjamin DK Jr, Bradley J, Guidos RJ, Jones RN, Murray BE, Bonomo RA, Gilbert D; Infectious Diseases Society of America. 10 x '20 Progress-development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis. 2013 Jun;56(12):1685-94.
http://grls.rosminzdrav.ru/
Registration of new ABx in Russia
02468
10121416
1981-1985
1986-1990
1991-1995
1996-2000
2001-2005
2006-2010
2010-2014
1513
10
43 3
1
7
Factors affecting interest of Big Pharma in development of anti-infective agents (AIA)
“we need a culture of cooperation between stakeholders; one that recognizes that there must be a balance between public health/clinical needs and the commercial realities of drug discovery and development”
Projan, S. Current Opinion in Microbiology 2003, 6, 427-430
• Development of new AIA is expensive, long-term process with high risk of failure
• Amendments to intellectual property laws has resulted in earlier loss of exclusivity
• Anti-infective drugs are considered ‘life-saving’ medications and are often the subject of aggressive price control
8
Combining science, tools and technologies Pfizer has a unique expertise in Anti-infectives area
9
In collaboration with leading Russian scientific societies Pfizer supports educational and scientific projects to increase awareness and understanding of antimicrobial resistance, to implement antibiotics stewardship programs and to optimize the use of antimicrobial medicines
Pfizer: support of educational and scientific projects in Russia
10
Pfizer: Support of the Governmental Strategy via transfer of technologies to Russia
Partner Products
PETROVAX PREVENAR
POLYSAN ZYVOX (PO)
NOVAMEDICA More than 30 SI including antimicrobial agents
11
Summary:
All these objectives are non achievable without the joint efforts of Professional Societies, Government and Industry
• Growing antibiotic resistance makes development new AIA as a crucial factor
• Optimization of ABx registration process is required to expedite new AIA authorization and provide earlier access to new effective medicines for patients with infectious disease
• Inclusion of all AIAs in EDL should be automatic upon registration to make it available for use in routine practice
• Implementation of antibiotics stewardship programs in all Russian hospitals is critical step to optimize use of existing and new anti-infectives and decrease budget impact.